Inhibition of human prostate stromal cell growth and smooth muscle contraction by thalidomide: A novel remedy in LUTS?
Inhibition of human prostate stromal cell growth and smooth muscle contraction by thalidomide: A novel remedy in LUTS?
复制标题
DOI：
10.1002/pros.24114
复制
发表时间：
2021-03
期刊：
影响因子：
--
通讯作者：
A. Tamalunas;C. Sauckel;A. Ciotkowska;B. Rutz;Ruixiao Wang;Ru Huang;Bingsheng Li;C. Stief;
中科院分区：
文献类型：
--
作者：
A. Tamalunas;C. Sauckel;A. Ciotkowska;B. Rutz;Ruixiao Wang;Ru Huang;Bingsheng Li;C. Stief;
良性前列腺增生的医学治疗以前列腺大小为目标，以防止疾病进展、并发症和手术，并以前列腺平滑肌张力为目标，以快速缓解下尿路症状。联合治疗仍然需要同时针对这两种疾病。然而，由于副作用和疗效之间的不利平衡，目前的药物不足。α1‐阻滞剂的有限疗效可能是由于非肾上腺素能介质，如内皮素‐1和血栓素A2 (TXA2)，即使在α1‐阻滞剂存在的情况下，它们也能保持前列腺平滑肌收缩。因此，未来更有效的选择需要同时针对α1 -肾上腺素能和非肾上腺素能收缩以及间质细胞生长。沙利度胺已被批准作为多种疾病的口服药物，包括治疗前列腺癌。因此，我们研究了沙利度胺对前列腺基质细胞功能和人前列腺平滑肌收缩的影响。
Medical treatment in benign prostatic hyperplasia targets prostate size to prevent disease progression, complications, and surgery, and prostate smooth muscle tone for rapid relief of lower urinary tract symptoms. Combination therapies are still required to target both at once. However, current medications are insufficient, due to an unfavorable balance between side effects and efficacy. The limited efficacy of α1‐blockers may be due to nonadrenergic mediators like endothelin‐1 and thromboxane A2 (TXA2), which keep up prostate smooth muscle contraction even in the presence of α1‐blockers. Consequently, future options with higher efficacy need to target α1‐adrenergic and nonadrenergic contractions as well as stromal cell growth at once. Thalidomide has been approved as an oral medication for various diseases, including the treatment of prostate cancer. Therefore, we investigated the effect of thalidomide on cellular functions of prostate stromal cells and human prostate smooth muscle contraction.